Educational Objectives

This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.

At the conclusion of this course, participants will be able to:

Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
Describe the logistis of bringing these new diagnostic and therapeutic technologies to clinical practice
Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT

With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era. New diagnostic and therapeutic agents with remarkable sensitivity and specificity are revolutionizing Nuclear Medicine and Oncology. This course will highlight the latest targeted imaging agents for neuroendocrine and prostate cancers (Ga-68 DOTATATE and Ga-68 PSMA PET/CT) as well as review important core concepts in PET/CT imaging and therapeutic Nuclear Medicine.

Target Audience

This course is intended for practicing radiologists, nuclear medicine physicians and radiologic nurses, physician assistants, technologists, residents, fellows and others who are interested in the clinical applications of PET and PET/CT.

Course Curriculum
Introduction to Theranostics – Phillip Kuo
Challenging and Instructive Abdomen and Pelvis PET/CT Review – Don Yoo
Important of Patient Preparation for PET/CT (Oncology and Cardiac Sarcoidosis) – Don Yoo
PET/CT in Head and Neck Cancer -Don Yoo
Update on Radioiodine Treatment for Thyroid Cancer and the Role of PET-CT – Don Yoo
Nuclear Medicine and Benign Thyroid Disease – Andrew Quon
Challenging and Interactive Chest PET/CT Review – Don Yoo
Neuroendocrine Tumor Imaging with DOTA PET/CT – Andrew Quon
Update on Nuclear Medicine for Infection and Inflammation – Don Yoo
Lu-177 PSMA Therapy-Lessons from the Vision Trial – Phillip Kuo
General Nuclear Medicine in 60 Minutes – Andrew Quon
PET Imaging for the Differential Diagnosis of Dementia – Phillip Kuo
Dopamine Transporter Imaging of Parkinsonian Syndromes – Phillip Kuo
Somatostatin Radiotherapy: Our New Era of Nuclear Medicine Therapeutics – Andrew Quon
Prostate Cancer PET Imaging – Andrew Quon
Neurotheranostics: Next Frontier for Health Span -Phillip Kuo

Release Date: 12/14/2023